Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2150-2156

  Wojtowicz Praga, Slawomir ^a   Torri, Jeff ^a   Johnson, Michael ^a   Steen, Virginia ^a   Marshall, John ^a   Ness, Elizabeth ^a   Dickson, Robert ^a   Sale, Mark ^a   Rasmussen, Henrik S ^a   Chiodo, Tina Avanzato ^a   Hawkins, Michael J ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GELATINASE A; GELATINASE B; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; FEMALE; HEADACHE; HUMAN; LIQUID CHROMATOGRAPHY; LUNG CANCER; MALE; MASS SPECTROMETRY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; POLYARTHRITIS; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TREATMENT OUTCOME; VERTIGO;

EID: 0031776982     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2150     Document Type: Article

References (22)

1. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ: Matrix metalloproteinase inhibitors. Invest New Drugs 15:61-75, 1997
2. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr: Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7:1434-1441, 1993
3. Belaaouaj A, Shipley JM, Kobayashi DK, et al: Human macrophage metalloelastase. Genomic organization, chromosomal location, gene linkage, and tissue-specific expression. J Biol Chem 270:14568-14575, 1995
4. Okada A, Bellocq JP, Rouyer N, et al: Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 92:2730-2734, 1995
5. Takino T, Sato H, Shinagawa A, et al: Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library - MT-MMPs form a unique membrane-type subclass in the MMPfamily. J Biol Chem 270:23013-23020, 1995
6. Fridman R, Toth M, Pena D, et al: Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 55:2548-2555, 1995
7. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64:327-336, 1991
8. Cao J, Sato H, Takino T, et al: The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation. J Biol Chem 270:801-805, 1995
9. Ray JM, Stetler-Stevenson WG: Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 14:908-917, 1995
10. Tryggvason K, Hoyhtya M, Pyke C: Type IV collagenases in invasive tumors. Breast Cancer Res Treat 24:209-218, 1993
11. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990
12. Fisher C, Gilbertson-Beadling S, Powers EA, et al: Interstitial collagenase is required for angiogenesis in vitro. Dev Biol 162:499-510, 1994
13. r 92,000 type IV collagenase is increased in plasma of patients with colon and breast cancer. Cancer Res 53:140-146, 1993
14. Brown PD, Bloxidge RE, Stuart NSA, et al: Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small cell lung carcinoma. J Natl Cancer Inst 85:574-578, 1993
15. Levy TD, Cioce V, Sobel ME, et al: Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 51:439-444, 1991
16. Zucker S, Lysik RM, Zarrabi HM, et al: Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment. Ann NY Acad Sci 732:248-262, 1994
17. Zucker S, Lysik RM, Zarrabi MH, et al: Type IV collagenase/ gelatinase (MMP-2) is not increased in plasma of patients with cancer. Cancer Epidemiol Biomarkers Prev 1:475-479, 1992
18. Wojtowicz-Praga S, Low J, Dickson R, et al: Phase I study of Batimastat (BB-94), a novel matrix metalloproteinase inhibitor in patients with advanced cancer. Invest New Drugs 14:193-202, 1996
19. Heussen C, Dowdle EB: Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102:196-202, 1980
20. Azzam HS, Arand G, Lippman ME, et al: Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst 85:1758-1764, 1993
21. Boasberg P, Harbaugh B, Roth B, et al: Marimastat, a novel matrix metalloproteinase inhibitor in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 15:258, 1996 (abstr)
22. Rosemurgy A, Harris J, Langleben A, et al: Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced carcinoma of the pancreas. Proc Am Soc Clin Oncol 15:207, 1996 (abstr)